文献速递心力衰竭与心肌病

现代基因组技术在心肌病遗传病因鉴定中的应用

Modern genomic techniques in the identification of genetic causes of cardiomyopathy.
PubMed 文献 · Heart · 2022-11-10

本综述总结了近十年二代测序(NGS)技术对非综合征型心肌病遗传学认识进展,包括已鉴定26个推定新致病基因(部分如FLNC、MTO1、HCN4已纳入常规诊断基因panel)、变异解读挑战与大规模人群对照队列的重要性、常见变异累加效应解释表型变异和低诊断率,以及西方背景下基因检测的临床效用与扩展测序建议。

要点

  • NGS已鉴定26个推定新致病基因,部分(FLNC、MTO1、HCN4)已进入常规诊断panel。
  • 大规模NGS人群对照队列对变异解读至关重要。
  • 常见多态位点累加效应可解释心肌病表型变异和测序低诊断率。

核心结论

  • NGS技术推动了非综合征型心肌病新致病基因的发现,但变异解读和常见变异作用仍需进一步研究。

研究设计与样本

  • 综述类文章,总结近十年NGS技术在非综合征型心肌病遗传病因鉴定中的进展。

主要发现

  • 已鉴定26个推定新致病基因,多来自全外显子测序,部分(FLNC、MTO1、HCN4)已纳入常规诊断基因panel。
  • 大规模NGS人群对照队列对变异解读重要。
  • 常见多态位点对心脏参数有累加效应,可能解释表型变异和测序研究低遗传诊断率。

关键数值与推荐

  • 西方背景下目前推荐对核心疾病基因进行NGS panel检测。
  • 对无欧洲血统且明确家族性疾病或严重儿童期疾病、panel测序无结果者,应考虑全外显子或全基因组测序。
  • 对于未检出致病变异的特发性扩张型心肌病和肥厚型心肌病患者,多基因风险评分的临床效用需进一步研究。

临床怎么用

  • 核心疾病基因NGS panel检测目前推荐用于心肌病基因检测。
  • 对特定人群(非欧洲血统明确家族性疾病或严重儿童期疾病)在panel无结果时可考虑全外显子或全基因组测序。
  • 多基因风险评分在未检出致病变异的扩张型心肌病和肥厚型心肌病中的临床应用需进一步研究。

局限性

  • 变异解读仍存在挑战。
  • 常见变异在遗传性心肌病中的作用仍在阐明中。
  • 多基因风险评分的临床效用尚未确定,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past three decades numerous disease-causing genes have been linked to the pathogenesis of heritable cardiomyopathies, but many causal genes are yet to be identified. Next-generation sequencing (NGS) platforms have revolutionised clinical testing capacity in familial cardiomyopathy. In this review, we summarise how NGS technologies have advanced our understanding of genetic non-syndromic cardiomyopathy over the last decade. First, 26 putative new disease-causing genes have been identified to date, mostly from whole-exome sequencing, and some of which (FLNC, MTO1, HCN4) have had a considerable clinical impact and are now included in routine diagnostic gene panels. Second, we consider challenges in variant interpretation and the importance of large-scale NGS population control cohorts for this purpose. Third, an emerging role of common variation in some forms of genetic cardiomyopathy is being elucidated through recent studies which have illustrated an additive effect of numerous polymorphic loci on cardiac parameters; this may explain phenotypic variability and low rates of genetic diagnosis from sequencing studies. Finally, we discuss the clinical utility of genetic testing in cardiomyopathy in Western settings, where NGS panel testing of core disease genes is currently recommended with possible implications for patient management. Given the findings of recent studies, whole-exome or whole-genome sequencing should be considered in patients of non-European ancestry with clearly familial disease, or severe paediatric disease, when no result is obtained on panel sequencing. The clinical utility of polygenic risk assessment needs to be investigated further in patients with unexplained dilated cardiomyopathy and hypertrophic cardiomyopathy in whom a pathogenic variant is not identified.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Spracklen TF, Keavney B, Laing N, et al. Modern genomic techniques in the identification of genetic causes of cardiomyopathy. Heart. 2022. PMID: 35140110. doi:10.1136/heartjnl-2021-320424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。